VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q3 2021
Holdings as of Sep 30, 2021, filed Nov 15, 2021. Long positions only; changes compare share counts with Q2 2021.
- Positions
- 26
- −3 vs. Q2 2021
- Portfolio value
- $778.5M
- −$45.9M (−5.6%) vs. Q2 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| VRDNViridian Therapeutics, Inc. | COM | 19,495 | $321.0K | <0.1% | 00.0% | Unchanged | History |
| TCDATricida, Inc. | COM | 390,707 | $1.81M | 0.2% | +390,707 | New | History |
| ATXSAstria Therapeutics, Inc. | COM | 538,999 | $4.76M | 0.6% | +538,999 | New | History |
| AKYAAkoya Biosciences, Inc. | COM | 400,000 | $5.58M | 0.7% | 00.0% | Unchanged | History |
| CVRXCVRx, Inc. | COM | 533,370 | $8.82M | 1.1% | −100,000−15.8% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 1,088,817 | $9.16M | 1.2% | 00.0% | Unchanged | History |
| PHVSPharvaris N.V. | COM | 552,882 | $9.80M | 1.3% | −350,000−38.8% | Reduced | History |
| LONALeonaBio, Inc. | COM | 1,196,196 | $11.2M | 1.4% | −288,809−19.4% | Reduced | History |
| ATYRaTYR PHARMA INC | COM NEW | 1,565,000 | $14.2M | 1.8% | +1,565,000 | New | History |
| CGEMCullinan Therapeutics, Inc. | COM | 706,050 | $15.9M | 2.0% | −270,095−27.7% | Reduced | History |
| CRVSCorvus Pharmaceuticals, Inc. | COM | 3,427,461 | $16.6M | 2.1% | +3,427,461 | New | History |
| NUVLNuvalent, Inc. | COM | 803,951 | $18.1M | 2.3% | +803,951 | New | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 1,127,272 | $18.8M | 2.4% | 00.0% | Unchanged | History |
| LENZLENZ Therapeutics, Inc. | COM | 1,612,617 | $26.4M | 3.4% | 00.0% | Unchanged | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 2,641,809 | $30.1M | 3.9% | 00.0% | Unchanged | History |
| KNTEKinnate Biopharma Inc. | COM | 1,473,014 | $33.9M | 4.4% | 00.0% | Unchanged | History |
| GHRSGH Research PLC | ORDINARY SHARES | 1,642,296 | $36.2M | 4.7% | +366,465+28.7% | Added | History |
| RLMDRelmada Therapeutics, Inc. | COM | 1,387,720 | $36.4M | 4.7% | 00.0% | Unchanged | History |
| TVTXTravere Therapeutics, Inc. | COM | 1,732,410 | $42.0M | 5.4% | +1,732,410 | New | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 1,536,193 | $42.3M | 5.4% | 00.0% | Unchanged | History |
| ALTAltimmune, Inc. | COM NEW | 3,800,000 | $43.0M | 5.5% | +300,000+8.6% | Added | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 16,047,286 | $44.0M | 5.6% | 00.0% | Unchanged | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 1,529,402 | $44.9M | 5.8% | +1,529,402 | New | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 1,098,174 | $59.3M | 7.6% | −142,436−11.5% | Reduced | History |
| ACRSAclaris Therapeutics, Inc. | COM | 4,563,962 | $82.2M | 10.6% | 00.0% | Unchanged | History |
| TILInstil Bio, Inc. | COM | 6,865,076 | $122.7M | 15.8% | 00.0% | Unchanged | History |
Sold out since Q2 2021 (10)
Positions held at the end of Q2 2021 that are gone from this filing.
| Security | Class | Shares in Q2 2021 | Value in Q2 2021 | % of portfolio in Q2 2021 | History |
|---|---|---|---|---|---|
| PRVBProvention Bio, Inc. | COM | 2,902,744 | $24.5M | 3.0% | History |
| Trillium Therapeutics Inc.89620X506 | COM NEW | 2,001,686 | $19.4M | 2.4% | – |
| EPIXESSA Pharma Inc. | COM NEW | 625,754 | $17.9M | 2.2% | History |
| RAPTRAPT Therapeutics, Inc. | COM | 391,000 | $12.4M | 1.5% | History |
| KURAKura Oncology, Inc. | COM | 575,000 | $12.0M | 1.5% | History |
| KROSKeros Therapeutics, Inc. | COM | 272,306 | $11.6M | 1.4% | History |
| ALGSAligos Therapeutics, Inc. | COM | 408,377 | $8.32M | 1.0% | History |
| HARPHarpoon Therapeutics, Inc. | COM | 512,005 | $7.10M | 0.9% | History |
| Catabasis Pharmaceuticals IN14875P206 | COM NEW | 3,234,000 | $6.82M | 0.8% | – |
| ACETAdicet Bio, Inc. | COM | 183,702 | $1.89M | 0.2% | History |